NCT00372567 - Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Gastrointestinal Stromal Tumor

Interventions

DRUG

sunitinib malate

37.5 mg daily

DRUG

imatinib mesylate

800mg daily

Trial Locations (25)

0

Pfizer Investigational Site, Lai Chi Kok

Pfizer Investigational Site, Tuenmen

Pfizer Investigational Site, Hong Kong

19111

Pfizer Investigational Site, Philadelphia

20133

Pfizer Investigational Site, Milan

22767

Pfizer Investigational Site, Hamburg

37075

Pfizer Investigational Site, Göttingen

40138

Pfizer Investigational Site, Bologna

46009

Pfizer Investigational Site, Valencia

48201

Pfizer Investigational Site, Detroit

48334

Pfizer Investigational Site, Farmington Hills

63110

Pfizer Investigational Site, St Louis

63141

Pfizer Investigational Site, Creve Coeur

63376

Pfizer Investigational Site, City of Saint Peters

71013

Pfizer Investigational Site, San Giovanni Rotondo

110-744

Pfizer Investigational Site, Seoul

135-710

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul

08036

Pfizer Investigational Site, Barcelona

G12 0YH

Pfizer Investigational Site, Glasgow

LS9 7TF

Pfizer Investigational Site, Leeds

NW1 2PG

Pfizer Investigational Site, London

SW3 6JJ

Pfizer Investigational Site, London

W1

Pfizer Investigational Site, London

M20 4BX

Pfizer Investigational Site, Manchester